Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Laquinimod Misses Key Study Goal

By Drug Discovery Trends Editor | August 2, 2011

NEW YORK (AP) – Teva Pharmaceutical Industries Ltd. said its experimental drug laquinimod, an oral treatment for multiple sclerosis, did not reduce patients’ annual relapse rate in a late-stage clinical trial.

The results showed that laquinimod was not more effective than a placebo. The study involved 1,331 patients who were treated with one of three options: laquinimod, a placebo, or Avonex, an older MS drug made by Biogen Idec Inc. The patients were assigned to the treatment groups at random. However, Teva said MRI scans showed the patients in the laquinimod and Avonex groups had more brain lesions, which indicates they had more severe multiple sclerosis.

The company said the patients in the laquinimod and Avonex groups had more overall lesions, and they had a greater number of recent lesions. Teva said if the study results are adjusted to remove the imbalance in the number of lesions, laquinimod met its main goal of lowering the relapse rate, and it also reduced brain volume loss and disability.

Teva and its partner Active Biotech said they still plan to seek approval of laquinimod in the U.S. and the European Union. In December, the companies said laquinimod met its main goal in its first late-stage trial. The companies said patients who took the drug were less likely to have a flare-up of the disease during treatment than patients who took a placebo. Patients who took laquinimod also reported less disability from the disease.

Teva also makes Copaxone, the top-selling multiple sclerosis therapy in the world. The Israeli company is the world’s largest seller of generic pharmaceuticals.

Date: August 1, 2011
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50